ES2092296T3 - Metodo de tratamiento de tejidos infectados. - Google Patents

Metodo de tratamiento de tejidos infectados.

Info

Publication number
ES2092296T3
ES2092296T3 ES93908585T ES93908585T ES2092296T3 ES 2092296 T3 ES2092296 T3 ES 2092296T3 ES 93908585 T ES93908585 T ES 93908585T ES 93908585 T ES93908585 T ES 93908585T ES 2092296 T3 ES2092296 T3 ES 2092296T3
Authority
ES
Spain
Prior art keywords
liposomes
trapped
treatment
infected region
sizes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908585T
Other languages
English (en)
Inventor
Martin C Woodle
Irma A J M Bakker-Woudenberg
Francis J Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Sequus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequus Pharmaceuticals Inc filed Critical Sequus Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2092296T3 publication Critical patent/ES2092296T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN METODO PARA EL TRATAMIENTO DE UN PUNTO DE INFECCION SISTEMATICA QUE CONSISTE EN ADMINISTRAR UN COMPUESTO TERAPEUTICO ATRAPADO EN LIPOSOMAS. TAMBIEN SE PRESENTA UNA COMPOSICION LIPOSOMAL Y UN METODO PARA LA PREPARACION DE LA COMPOSICION LIPOSOMAL A UTILIZAR PARA CONCENTRAR UN COMPUESTO TERAPEUTICO EN UNA REGION INFECTADA A TRAVES DEL FLUJO SANGUINEO. LOS LIPOSOMAS, QUE CONTIENEN EL AGENTE DE FORMA ATRAPADA, SE COMPONEN DE LIPIDOS FORMADORES DE VESICULAS, UN LIPIDO FORMADOR DE VESICULAS DERIVADO CON UN POLIMERO HIDROFILICO BIOCOMPATIBLE, Y SUS TAMAÑOS SE SELECCIONAN DE UNA GAMA DE TAMAÑOS DE ENTRE 0,07 Y 0,2 MICRAS. TRAS LA ADMINISTRACION PARENTERAL, LA REGION INFECTADA TOMA DE FORMA SELECTIVA LOS LIPOSOMAS EN UN PERIODO DE TIEMPO DE 24 A 48 HORAS, PARA LIBERAR EL COMPUESTO ATRAPADO EN LA REGION INFECTADA.
ES93908585T 1992-03-27 1993-03-24 Metodo de tratamiento de tejidos infectados. Expired - Lifetime ES2092296T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/858,171 US5843473A (en) 1989-10-20 1992-03-27 Method of treatment of infected tissues

Publications (1)

Publication Number Publication Date
ES2092296T3 true ES2092296T3 (es) 1996-11-16

Family

ID=25327664

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908585T Expired - Lifetime ES2092296T3 (es) 1992-03-27 1993-03-24 Metodo de tratamiento de tejidos infectados.

Country Status (7)

Country Link
US (1) US5843473A (es)
EP (1) EP0632719B1 (es)
AT (1) ATE142483T1 (es)
DE (1) DE69304685T2 (es)
DK (1) DK0632719T3 (es)
ES (1) ES2092296T3 (es)
WO (1) WO1993019738A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US6645463B1 (en) 1994-05-16 2003-11-11 The Board Of Regents Of The University Of Michigan Blood-pool selective carrier for lipophilic imaging agents
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
EP0784470B1 (en) * 1994-10-03 2003-08-13 INFECTIO RECHERCHE Inc. Liposome-formulations for treatment of viral diseases
US8071737B2 (en) * 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US6673364B1 (en) 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
US20060089751A1 (en) * 1997-01-27 2006-04-27 Ewa Herbst Electronic delivery systems and methods with feedback
US20110230857A1 (en) * 1997-01-27 2011-09-22 Ewa Herbst Electronic delivery systems and methods with feedback
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
WO1998046275A2 (en) * 1997-04-11 1998-10-22 The Board Of Regents Of The University Of Michigan Blood-pool carrier for lipophilic imaging agents
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US20010003580A1 (en) * 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
AU4196099A (en) * 1998-05-21 1999-12-06 Isis Pharmaceuticals, Inc. Long-circulating liposomal compositions
CA2335638A1 (en) * 1998-06-19 1999-12-23 Ronald K. Scheule Cationic amphiphile micellar complexes
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US20030021792A1 (en) * 2001-06-08 2003-01-30 Roben Paul W. Tissue-specific endothelial membrane proteins
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
US20030147944A1 (en) * 1999-12-10 2003-08-07 Mayer Lawrence D Lipid carrier compositions with protected surface reactive functions
WO2001085131A2 (en) * 2000-05-11 2001-11-15 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
JP2005525992A (ja) * 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
ES2387886T3 (es) * 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
JP2006502968A (ja) * 2002-02-21 2006-01-26 ユニヴエルシタ デリ スツディ ディ パヴィア 細菌性コラーゲン結合タンパク質に対して交差反応性のモノクロナール抗体
JP2005530704A (ja) * 2002-03-05 2005-10-13 トランセイブ， インク． 細胞内感染を予防及び治療するための吸入システム
AR036316A1 (es) * 2002-08-29 2004-08-25 Monte Verde S A Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion
PT1581236E (pt) * 2002-10-29 2013-12-24 Insmed Inc Libertação prolongada de anti-infecciosos
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
WO2006039369A1 (en) * 2004-09-29 2006-04-13 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
US20070105757A1 (en) * 2005-10-31 2007-05-10 May Thomas B Vancomycin formulations having reduced amount of histamine
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
DK2019683T4 (da) 2006-04-25 2022-08-29 Univ California Indgivelse af vækstfaktorer til behandling af CNS-lidelser
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
JP5333970B2 (ja) * 2007-03-20 2013-11-06 国立大学法人大阪大学 心筋梗塞の予防および／または治療薬
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
EP3486653A1 (en) 2007-05-24 2019-05-22 The United States Government as represented by The Department of Veterans Affairs Treatment of skeletal muscle disorder using ent2
WO2011160110A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
US20140023696A1 (en) * 2012-07-20 2014-01-23 Frederick Timothy Guilford Treatment for idiopathic pulmonary fibrosis
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
US20140234397A1 (en) * 2013-02-15 2014-08-21 Lou Ann Brown Treatment of klebsiella pneumoniae with liposomally formulated glutathione
US10039716B2 (en) * 2013-03-13 2018-08-07 Mallinckrodt Llc Liposomal cisplatin compositions for cancer therapy
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
US20170281541A1 (en) * 2014-09-05 2017-10-05 The Johns Hopkins University Liposome-based mucus-penetrating particles for mucosal delivery
EP4154915A1 (en) 2014-12-31 2023-03-29 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
KR20180133527A (ko) 2016-05-04 2018-12-14 랜티우스 메디컬 이메징, 인크. 초음파 조영제의 제조 방법 및 장치
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11052158B2 (en) * 2016-08-18 2021-07-06 Troy Bremer Delivery of urea to cells of the macula and retina using liposome constructs
EP3731846A4 (en) * 2017-12-29 2022-03-02 Wayne State University DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF INFECTION
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
US20220339136A1 (en) * 2019-08-30 2022-10-27 United States Government As Represented By The Department Of Veterans Affairs Liposomal troponoid compound formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
JPS6376862A (ja) * 1986-09-17 1988-04-07 Nippon Denso Co Ltd 表面硬化層を有するアルミニウム部材
IL97538A (en) * 1986-12-23 1995-03-15 Liposome Co Inc Multilamellar liposomes containing nonphosphate guanindino aminoglycosides and their preparation.
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JP2666345B2 (ja) * 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
JPH04234841A (ja) * 1988-07-08 1992-08-24 Mitsubishi Rayon Co Ltd 光学活性化合物及び液晶組成物
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5079234A (en) * 1989-03-23 1992-01-07 Bristol-Myers Squibb Co. Inhibitors of aminoglycoside nephrotoxicity
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time

Also Published As

Publication number Publication date
WO1993019738A1 (en) 1993-10-14
EP0632719B1 (en) 1996-09-11
DK0632719T3 (da) 1997-09-15
ATE142483T1 (de) 1996-09-15
EP0632719A1 (en) 1995-01-11
DE69304685D1 (de) 1996-10-17
US5843473A (en) 1998-12-01
DE69304685T2 (de) 1997-04-03

Similar Documents

Publication Publication Date Title
ES2092296T3 (es) Metodo de tratamiento de tejidos infectados.
ES2071976T3 (es) Metodo de tratamiento de tumores solidos y composicion.
ATE152614T1 (de) Mittel zur behandlung entzündeter gewebe
ES2136618T3 (es) Cicatrizacion de heridas.
SE8703034L (sv) Oralt terapeutiskt system med systemisk verkan
ES2103276T3 (es) Composicion para la activacion del sistema inmunitario.
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
HUT63564A (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
ES2167611T3 (es) Formulaciones de gel que contienen factores de crecimiento.
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
DK0502092T3 (da) Oralt præparat til behandling af inflammatoriske tarmsygdomme
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
US5863941A (en) Method and composition of a topical treatment of inner ear and labyrinth symptoms
DK98089A (da) Medikament-lipid-systemer med lav toxicitet
PT904067E (pt) Dextrometorfan como agente antitussico administrado transdermicamente
ES2066062T3 (es) Preparacion de liberacion sostenida para administracion al cerebro.
JP2020528895A (ja) 腫瘍転移を処置する方法
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
ES2194832T3 (es) Formulaciones de ditiazem con absorcion controlada.
US3019167A (en) Method of administering streptokinase systemically
DK211489A (da) Farmaceutisk praeparat

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 632719

Country of ref document: ES